Pfizer Announces a Research Grant RFP

Inflammatory and Immune-Mediated Dermatologic Disorders Research RFP: Established Investigators Competitive Grant Program

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an external expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.
## Competitive Grant Program Eligibility

<table>
<thead>
<tr>
<th>Geographic Scope</th>
<th>United States</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Applicant Eligibility Criteria</strong></td>
<td>To be eligible:</td>
</tr>
<tr>
<td></td>
<td>• The institution and principal investigator (PI) must be based in the US</td>
</tr>
<tr>
<td></td>
<td>• Only organizations are eligible to receive grants, not individuals or medical practice groups.</td>
</tr>
<tr>
<td></td>
<td>• The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.</td>
</tr>
<tr>
<td></td>
<td>• Established Investigator is defined as an investigator that is more than 10 years past their terminal training.</td>
</tr>
<tr>
<td></td>
<td>• Applicant must be affiliated with a host institution.</td>
</tr>
</tbody>
</table>

### Requirements

<table>
<thead>
<tr>
<th>Date RFP Issued</th>
<th>December 17, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Area</td>
<td>Inflammatory and Immune-mediated Dermatologic Disorders</td>
</tr>
<tr>
<td>Area of Interest Focus</td>
<td>The intent of this Request for Proposal (RFP) is to support preclinical, clinical and outcomes research through a competitive grant program with the intent to increase medical knowledge in the diagnosis and management of inflammatory and immune-mediated dermatologic disorders. In particular, Pfizer has interest in alopecia areata (AA) and atopic dermatitis (AD), although other inflammatory skin conditions may be considered.</td>
</tr>
</tbody>
</table>

#### Areas of Research Focus: Alopecia Areata (AA)

- Overall burden of disease, specifically psychosocial impact of AA and impact of treatment on the burden
- Mechanistic insights into the role of the JAK/STAT and TEC pathways in AA
- Pharmacogenomic studies in AA dermatitis to identify potential responders to JAK inhibition and differences in clinical course, including
Inflammatory and Immune-Mediated Dermatologic Disorders: Established Investigators

### Areas of Research Focus: Atopic Dermatitis (AD)
- Real-world evidence (RWE) in AD
- Pharmacogenomic studies in AD to identify potential responders to JAK inhibition, including phenotype or endotype differences among patient subgroups
- Validation of AD disease severity measures in skin of color
- Identification of immunophenotypic differences in clinical course and treatment response of AD in skin of color

### Out of Scope
- Research proposals that conflict with ongoing Pfizer-sponsored trials or future development plans are out of scope.
- Research proposals that require drug supply for investigational JAK-inhibitors

### Expected Approximate Monetary Range of Grant Applications
- Individual projects requesting up to $175,000 will be considered.
- The amount of the grant Pfizer will be prepared to fund for any project will depend upon the expert Pfizer review panel’s evaluation of the proposal and costs involved, and will be stated clearly in the approval notification.

### Key Dates
- RFP release date: December 17, 2021
- Full Proposal due date: February 24, 2022
- Review of Full Proposals by ERP: April 2022
- Anticipated Full Proposal Notification Date: June 2022

### How to Apply
- Please go to [www.cybergrants.com/pfizer/Research](http://www.cybergrants.com/pfizer/Research) and sign in. First-time users should click "Create your password".

Requirements for submission:
- Select the following Competitive Grant Program Name: 2021 I&I L Inflammatory and Immune-Mediated Dermatologic Disorders Established
- Complete all required sections of the online application. See Appendix A for additional details
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.
### Questions:
- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Amanda Solis (amanda.solis@pfizer.com), with the subject line “Inflammatory and Immune-Mediated Dermatologic Disorders – Established.”
- Please click [here](#) to view Frequently Asked Questions regarding the Competitive Grant Program

### Review and Approval Process
- Grant requests received in response to a specific RFP are reviewed by an expert review panel (ERP) to make final grant decisions.
- The panels are comprised of professionals from the medical community with advanced degrees and expertise in particular clinical areas, or specific needs of a geographic region/learner group, or expertise in research, continuing professional development or quality improvement.

### Mechanism by which Applicants will be Notified:
- All applicants will be notified via email by the dates noted above
- Applicants may be asked for additional clarification during the review period
Appendix A

Full Proposal/Protocol

Applications will be accepted via the online portal. Full Proposal/Protocol documents should be no longer than 10-15 pages in length (12-point font and 1-inch margins) excluding Organization Detail and References. When uploading your Full Proposal/Protocol please ensure it addresses the following:

<table>
<thead>
<tr>
<th>Goals and Objectives</th>
<th>• Provide the main goal of the study and the study population (if applicable). Provide a detailed definition that is directly linked to the primary objective</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessment of Need for the Project</td>
<td>• This should reflect your study rationale. Provide a brief description of the medical/scientific question and the rationale of how this trial or study addresses the question</td>
</tr>
</tbody>
</table>
| Target Audience            | • Describe the primary audience(s) targeted for this project. For Investigator Sponsored Clinical Trials, please specify the age, gender and other demographic information for trial population  
• Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population |
| Project Design and Methods | • Describe concisely the research design and methods for achieving the stated goals. For a clinical interventional study, include inclusion/exclusion criteria, treatment plan and statistical plan |
| Innovation                 | • Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project |
| Evaluation and Outcomes    | • Specify type and frequency of safety, efficacy, and/or outcome measures. Also indicate the method(s) used to assess measures  
• Provide a publication plan describing intended submission of abstracts to (a) congress(es) or intended submission of (a) publication(s) to peer-reviewed journals. All publications must follow ICH guidelines |
| Anticipated Project Timeline | • Provide an anticipated timeline for your project including project start/end dates |
| Additional Information     | • If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here. |
### Organization Detail
- This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and “other”]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project.

### References
- Bibliography of relevant references